Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis—a spin-off study of the NORD-STAR randomized clinical trial

Fig. 2

IFNα protein levels are reduced after treatment initiation with conventional and biologic treatment strategies. IFNα protein levels in plasma from patients with early RA before (d1) and 24 weeks after treatment initiation (w24) with A methotrexate + prednisone (n = 85), B methotrexate + TNFi (n = 87), C methotrexate + CTLA-4Ig (n = 91), and D methotrexate + IL-6Ri (n = 82). Wilcoxon matched-pairs signed rank test. E Absolute difference in IFNα plasma protein levels between week 24 and day 1 in four treatment arms. MTX (methotrexate), TNFi (certolizumab-pegol), CTLA-4Ig (abatacept), and IL-6Ri (tocilizumab). Kruskal-Wallis test followed by Dunn’s multiple comparison test

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us